Scarica l'app Stockscreener
11.31
1.39%
-0.16
Dopo l'orario di chiusura:
11.31
Precedente Chiudi:
$11.47
Aprire:
$11.34
Volume 24 ore:
169.32K
Relative Volume:
0.47
Capitalizzazione di mercato:
$628.02M
Reddito:
-
Utile/perdita netta:
$-117.99M
Rapporto P/E:
-5.2858
EPS:
-2.1397
Flusso di cassa netto:
$-79.92M
1 W Prestazione:
-7.07%
1M Prestazione:
-11.36%
6M Prestazione:
-60.52%
1 anno Prestazione:
-34.34%
Intervallo 1D:
$11.00
$11.60
Intervallo di 1 settimana:
$11.00
$12.66
Portata 52W:
$10.52
$34.48
Oculis Holding Ag Stock (OCS) Company Profile
Nome
Oculis Holding Ag
Settore
Industria
Telefono
-
Indirizzo
-
Compare OCS vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
11.31 | 636.91M | 0 | -117.99M | -79.92M | -2.1397 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-19 | Iniziato | JP Morgan | Overweight |
| 2025-08-27 | Iniziato | Needham | Buy |
| 2023-12-05 | Iniziato | Chardan Capital Markets | Buy |
| 2023-10-05 | Iniziato | Stifel | Buy |
| 2023-06-14 | Iniziato | BofA Securities | Buy |
| 2023-06-12 | Iniziato | H.C. Wainwright | Buy |
| 2023-06-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-05-10 | Iniziato | Pareto | Buy |
| 2023-04-28 | Iniziato | Wedbush | Outperform |
Mostra tutto
Oculis Holding Ag Borsa (OCS) Ultime notizie
Precision Trading with Oculis Holding Ag (OCS) Risk Zones - Stock Traders Daily
Oculis doses first patient in phase 3 privosegtor trial for ON - Glance by Eyes On Eyecare
Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade - Yahoo Finance
Oculis Holding - thepharmaletter.com
H.C. Wainwright reiterates Oculis stock rating on trial start - Investing.com
Oculis Holding AG Ordinary shares (NASDAQ: OCS) Share Price, OCS Stock News, OCS Share Price & Updates - kalkine.ca
There Is No Approved Specific Treatment for Acute Optic Neuritis. Oculis Is Testing One. - stocktitan.net
Enterprise value to revenue forward of Oculis Holding AG – FWB:CR5 - TradingView
Oculis (OCS) Daily Review: Rises 0.38% to $13.19 at the Close; Chart Reference: $12.53 and $13.85 Define the Nearby Reference Levels for the Current SessionAnchored VWAP - vinanet.vn
Oculis (OCSAW) Session-Level Review: Ends Up by 6.00% at $5.04 in the Latest Session; Current Setup: the Near-Term Reference Band Stretches From $4.79 to $5.29 in the Current UpdateAggressive Growth Picks - vinanet.vn
Oculis Holding (OCS) Advances 0.94% as Shares Hold Above Key SupportDouble Top - vinanet.vn
Stifel reiterates Buy rating on Oculis stock, $40 target By Investing.com - Investing.com Nigeria
The Technical Signals Behind (OCS) That Institutions Follow - Stock Traders Daily
Four Oculis directors' restricted stock units vest in Aug. 13 notifications - Stock Titan
Oculis (NASDAQ:OCS) Price Target Cut to $20.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect? - Zacks Investment Research
Stifel reiterates Buy rating on Oculis stock, $40 target - Investing.com
Oculis Holding AG Warrants (OCSAW) Hold Steady at $4.50 as Consolidation Range NarrowsVolatility Breakout Picks - Vinanet
Oculis buys out privosegtor’s global rights from Accure - Glance by Eyes On Eyecare
HC Wainwright Has Negative Estimate for Oculis Q3 Earnings - MarketBeat
Oculis rebuilds pipeline with Privosegtor buy from Accure - AllSci
Oculis Holding AG (OCS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Oculis Announces Asset Purchase Agreement With Accure Therapeutics, Posts Q2 2026 Financial Results - VisionMonday.com
Oculis Holding (OCS) inks $3.8M cash-plus-shares deal for Privosegtor rights - Stock Titan
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company - The Manila Times
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, ... - pmg-ky3.com
Oculis to buy Accure rights to Privosegtor for $3.8 million plus up to 2,050,000 shares - Bitget
Oculis acquires full rights to Privosegtor, boo... - Pluang
Oculis to Acquire Full Global Rights to Privosegtor from Accure Therapeutics in Strategic Asset Purchase - Quiver Quantitative
Oculis Signs Asset Purchase Agreement with Accure - GlobeNewswire
Oculis Holding AG (OCS) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Oculis (NASDAQ:OCS) Announces Quarterly Earnings Results - MarketBeat
Oculis Holding AG (OCS) stock price, news, quote and history - Yahoo Finance UK
Oculis Holding earnings beat by CHF0.23, revenue topped estimates - Investing.com Nigeria
Wall Street Zen Upgrades Oculis (NASDAQ:OCS) to Sell - MarketBeat
Oculis Holding AG (OCS) Stock News Today - TradingKey
Oculis Holding AG (OCS) Stock Analysis: Navigating a 190.92% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Oculis Reports Q2 2026 Financial Results and Provides Company Update - The Manila Times
Oculis Holding AG Stock 12‑Month Price Target Cut to $36.26, Implies 193% Upside - TradingView
Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Oculis Holding AG reports results for the quarter ended June 30Earnings Summary - TradingView
Oculis Q2 2026 Results: Finance Gains Narrow the Net Loss Despite Higher Costs - TradingKey
OCS: Privosegtor and Licaminlimab trials advance, with strong cash reserves supporting long-term growth - TradingView
Oculis (NASDAQ: OCS) pivots to neuro-ophthalmology as H1 loss falls - stocktitan.net
Earnings To Watch: Oculis Holding AG (OCS) Reports Q2 2026 Result - Yahoo Finance
Oculis Receives Positive FDA Feedback for Privosegtor Development in Acute Multiple Sclerosis Relapses - Quiver Quantitative
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses - Yahoo Finance Singapore
Oculis Holding (OCS) Holds Near $11.31 as Buyers Defend Key Support ZoneStock Picks - vinanet.vn
Oculis Holding AG (OCS) Q1 2026 Earnings: Wider-than-Expected Loss Amid Development ProgressInvestor Earnings Call - vinanet.vn
Oculis Holding AG Revenue Breakdown – NASDAQ:OCSAW - TradingView
Oculis Holding Ag Azioni (OCS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):